Loading...
XSTO
AXIC A
Market cap11mUSD
Oct 09, Last price  
1.93SEK
1D
9.04%
1Q
-19.25%
Jan 2017
-63.58%
IPO
-82.82%
Name

aXichem AB (publ)

Chart & performance

D1W1MN
XSTO:AXIC A chart
P/E
—
P/S
7.09
EPS
—
Div yield, %
—
Shrs. gr., 5y
29.17%
Rev. gr., 5y
71.95%
Revenues
18m
+115.24%
000000376,000000344,000343,0001,227,0004,362,0005,007,0001,809,0008,570,00018,446,000
Net income
-18m
L-1.01%
-1,048,343-1,714,510-2,373,899-2,357,067-3,483,130-3,656,563-5,628,000-7,423,000-6,072,000-7,375,000-9,927,000-12,444,000-13,515,000-15,093,000-17,260,000-20,811,000-17,813,000-17,633,000
CFO
-11m
L-1.36%
7,417,083-2,998,397-1,131,528-428,503-4,885,777-4,293,957-9,014,000-7,977,000-5,526,000-7,688,000-7,461,000-12,294,000-11,694,000-15,595,000-19,098,000-15,677,000-11,503,000-11,346,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.

Key people

Lucas Altepost
Deputy Chief Executive Officer · since 2017
Jakob Axelsson
Director · since 2015
Jorn Berthelsen
Director · since 2017
Jan Gustavsson
Chairman of the Board · since 2017
Gunilla Savring
Director · since 2017
URL
https://www.axichem.se/
IPO date
Jul 10, 2008
Employees
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Södergatan 26
Malmö, M 211 34
SE
Address
Sodergatan 26
Malmo, M 211 34
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT